FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.
Read the full article on the original site.
Read Full Article